Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498.
about
Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft ModelCD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating CellsCancer metastases: challenges and opportunitiesTargeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence.Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
P2860
Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-CD44 mAb for the treatmen ...... s: evaluation of WO2013063498.
@en
type
label
Anti-CD44 mAb for the treatmen ...... s: evaluation of WO2013063498.
@en
prefLabel
Anti-CD44 mAb for the treatmen ...... s: evaluation of WO2013063498.
@en
P2860
P1476
Anti-CD44 mAb for the treatmen ...... s: evaluation of WO2013063498.
@en
P2093
Giovanni D'Arena
Silvia Deaglio
P2860
P304
P356
10.1517/13543776.2014.915942
P407
P577
2014-05-06T00:00:00Z